Episode 234: COVID-19 Vaccine Rollout Faces Challenges In New England; The Lasting Impact Of Pop Star Selena

Illustration by Iliana Galvez

The Pfizer and Moderna COVID-19 vaccines are the first of their kind to use mRNA. This week on NEXT, how this new experimental technology could help fight diseases like cancer and cystic fibrosis. Plus, some of the challenges of vaccine distribution in New England. And a new podcast, “Anything For Selena,” explores the Mexican American pop star’s legacy and what it shows us about belonging in America.


Maria Garcia, senior editor of WBUR’s The ARTery and host of the new podcast, “Anything for Selena.” 


Angus Chen, reporter for WBUR’s CommonHealth
Why Some Scientists See ‘Unlimited’ Possibility In Technology Behind COVID-19 Vaccines

Brenda Leon, Report For America reporter at Connecticut Public Radio
Yale Doctor Shares His COVID-19 Vaccine Experience With Spanish-Speaking Patients

Casey McDermott, investigative data reporter and editor at New Hampshire Public Radio
Efforts to Vaccinate N.H.’s Long-Term Care Community Haven’t Been Easy, For Facilities or Families

Carrie Saldo, reporter at GBH
For A Props Warehouse In Central Mass., Pandemic Binge Watching Is Big Business

Ray Hardman, reporter at Connecticut Public Radio
Sea Shanties Take Over TikTok – What’s the Fascination?

About NEXT

NEXT is produced at Connecticut Public Radio
Host/Producer: Morgan Springer
Freelance Producer: Lily Tyson
Executive Editor: Vanessa de la Torre
Senior Director: Catie Talarski
Music: Todd Merrell, “New England” by Goodnight Blue Moon, “Brain Disease” by Anjimile, “The Hollow” by The Wolff Sisters, “Como la Flor,” “Dreaming of You” and “Amor Prohibido” by Selena and “The Wellerman – Tiktok Sea Shanty mashup 2021” by Dubbac Media.   

New to NEXT? You can find every episode or one you missed within our archives

We want your feedback! Send critiques, suggestions, questions and ideas to next@ctpublic.org. Help us spread the word! If you like what you hear, rate and review us on iTunes.

Follow us on Facebook and Twitter.